User login
Article Type
Changed
Display Headline
The Best of 2020: The RA Report
Read this supplement to Rheumatology News here.
In this issue:
- Synovial biopsy findings drive precision medicine closer to the clinic
- Ready for PRIME time? Newly identified cells predict flares
- Rheumatologists’ prescriptions of biosimilars stagnate
- Methotrexate in terms of ILD concerns, poor adherence, and low-dose AEs 10-13 TNF inhibitors linked to risk for inflammatory CNS events
- Hypersensitivity reactions to biologics differentiated
- Repeat latent TB testing focuses on new risks
Publications
Sections
Read this supplement to Rheumatology News here.
In this issue:
- Synovial biopsy findings drive precision medicine closer to the clinic
- Ready for PRIME time? Newly identified cells predict flares
- Rheumatologists’ prescriptions of biosimilars stagnate
- Methotrexate in terms of ILD concerns, poor adherence, and low-dose AEs 10-13 TNF inhibitors linked to risk for inflammatory CNS events
- Hypersensitivity reactions to biologics differentiated
- Repeat latent TB testing focuses on new risks
Read this supplement to Rheumatology News here.
In this issue:
- Synovial biopsy findings drive precision medicine closer to the clinic
- Ready for PRIME time? Newly identified cells predict flares
- Rheumatologists’ prescriptions of biosimilars stagnate
- Methotrexate in terms of ILD concerns, poor adherence, and low-dose AEs 10-13 TNF inhibitors linked to risk for inflammatory CNS events
- Hypersensitivity reactions to biologics differentiated
- Repeat latent TB testing focuses on new risks
Publications
Publications
Article Type
Display Headline
The Best of 2020: The RA Report
Display Headline
The Best of 2020: The RA Report
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Consolidated Pubs: Do Not Show Source Publication Logo
Use ProPublica
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Medscape Article
Display survey writer